Biogen Inc

Morningstar and Sustainalytics offer complementary methodologies.

Details on Alzheimer's drug candidate are encouraging, but uncertainty remains.

We assign a 30% probability of approval of the wide-moat firm's Alzheimer's drug.

Gold-rated Primecap Odyssey Stock is a compelling actively managed choice in the large-cap space.

Putting recent results in context.

Innovation and M&A may drive these firms' fortunes.

T. Rowe Price's David Giroux and Wellington Management's Jean Hynes talk value investing, innovation in healthcare, and where they're finding opportunity.

We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended March 29.

Even after recent failed drug trials, we think the company’s undervalued.

Primecap’s managers have been here before and have proven adept at taking advantage of such opportunities.

We think the market underappreciates some large pharma and biotech names.

This Gold-rated large-cap fund's multimanager approach has richly rewarded investors.

Reports are due from Alphabet, Facebook, and Amazon as well as big names in consumer goods, autos, and oil. Plus, the advanced reading of second-quarter GDP.

We look at dividend stocks in the utilities sector, drugmakers on the cutting edge, and a large-growth holding on this week's episode.

These manufacturing experts look undervalued today.

Alzheimer's therapy shows promising results.

Take a look at Morningstar analysts' nine 'exponential technology' themes and some undervalued stocks poised to benefit from them.

The Morningstar Wide Moat Focus Index adds some healthcare and tech, eschews some financial services stocks.

These names all gained more than 10% during the past three months yet remain undervalued by our metrics.

These stocks are positioned to outperform their peers, and they also score well on environmental, social, and governance metrics.